1, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseases

Details for Australian Patent Application No. 2008339993 (hide)

Owner Glaxo Group Limited

Inventors Hurst, David Nigel; Heightman, Thomas Daniel; Johnson, Christopher Norbert; Skidmore, John; Heer, Jag Paul; Wall, Ian David

Agent Davies Collison Cave

Pub. Number AU-A-2008339993

PCT Pub. Number WO2009/080730

Priority 0725102.8 21.12.07 GB

Filing date 19 December 2008

Wipo publication date 2 July 2009

International Classifications

C07D 413/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

1 July 2010 PCT application entered the National Phase

  PCT publication WO2009/080730 Priority application(s): WO2009/080730

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008340000-Solar energy reflector

2008339988-Oxadiazole derivatives active on sphingosine-1-phosphate (S1P)